| Immune checkpoint association |
| durvalumab plus tremelimumab |
| mHNSCC - 2nd line (L2) | |
| mHNSCC - L2 - all population 4 | |
| mHNSCC - L2 - PDL1 negative 2 | |
| mHNSCC - L2 - PDL1 positive 1 | |
Comparator:
vs Standard of Care (SoC); vs durvalumab alone; vs tremelimumab;
Risk of bias:
low;
some concerns;
high;
NA;